Copolymer

Copaiba (Copaifera spp.) Oleoresin: A Comprehensive Reference

1. Identity: Botanical Names, Natural Source, and Preparations

Botanical and Chemical Identity

Copaiba is an oleoresin obtained from the trunk of several pinnate-leaved South American leguminous trees belonging to the genus Copaifera. The copaiba trees belong to the genus Copaifera, family Fabaceae, and subfamily Caesalpinoideae. There are over 70 species in total. The most important commercial sources of copaiba oil are C. langsdorffii, C. officinalis, and C. reticulata, and the most prized copaiba oils are rich in β-caryophyllene.

Copaiba balsam (INCI: Copaifera Officinalis Resin) is a natural, resinous, oil-containing active ingredient from the trunk of the copaiba tree. The thick, transparent exudate varies in color from light gold to dark brown, depending on the ratio of resin to essential oil. The term "copaiba" itself has indigenous roots: the name copaiba is derived from the Tupi Indian word cupa-yba, which roughly translates to "deposit tree." This term refers to both the Copaifera tree and the copaiba resin that is stored inside the tree.

These trees grow in the Amazon Basin, covering regions in Brazil, Peru, Colombia, and Venezuela. Copaifera trees can grow up to 30 metres tall and take several years to mature before they can be tapped for their resin. The resin is tapped from standing trees, with an individual tree yielding 40 L (11 US gal) per year.

Common Forms and Preparations

Copaiba balsam is a sap-like substance (oleoresin) collected from the trunk of trees that belong to the Copaifera species. Copaiba balsam is processed to make copaiba oil. Both copaiba balsam and copaiba oil are used to make medicine.

The balsam may be steam distilled to give copaiba oil, a colorless to light yellow liquid with the characteristic odor of the balsam and an aromatic, slightly bitter, pungent taste. The aroma of copaiba resin is described as characteristically copaiba and balsamic, whilst that of the essential oil is described as "warm, balsamic, spicy, peppery, metallic, woody, creamy, and labdanum."

Current supplement forms include: copaiba supplements available in capsules or softgels that contain standardized amounts of copaiba oleoresin. Topical preparations such as creams, gels, and ointments are also described in research literature. In manufacturing, copaiba balsam and copaiba oil are used in soaps, cosmetics, and perfumes. In pharmaceutical preparations, both copaiba balsam and copaiba oil are used in cough medicines and diuretics. In foods and beverages, copaiba balsam is used as an ingredient.

2. Traditional and Historical Use

Pre-Columbian and Indigenous Amazonian Use

The oleoresin of Copaifera trees has been widely used as a traditional medicine in Neotropical regions for thousands of years and remains a popular treatment for a variety of ailments. The Tupi-Guarani people of Brazil are believed to be some of the first to use copaiba in traditional medicine, applying it to treat wounds, skin conditions, and respiratory ailments. They also used the oil in spiritual rituals for its ability to purify and balance the body.

Copaiba oil-resins extracted have been used in folk medicine dating back to the 16th century by the natives of north and northeastern Brazil. The folk remedies were administered orally or used as an ointment in the treatment of various diseases. In Panama, the Yaviza people mix the resin with honey and give it to newborns to impart knowledge and ward off hexes. Within the Peruvian Amazon near Iquitos, it is also used as an insect repellent.

Historically, copaiba resin was one of the primary go-to remedies for Amazonian tribes. It was applied directly to cuts, burns, and insect bites, offering relief and promoting faster healing. In the Amazon, local tribes would ingest copaiba to treat respiratory issues, urinary tract infections, skin diseases, and a plethora of other illnesses.

Introduction to Europe and Broader Ethnomedicinal Record

Copaiba was first mentioned in 1534 in a report that was sent to Pope Leo X, but the Copaifera tree was not mentioned until 1648. As early as the 16th century, European explorers learned about copaiba and brought it back to Europe, where it was incorporated into herbal medicine for treating respiratory conditions and digestive issues.

Originally considered in Europe as a panacea, and later as the anti-gonorrhea remedy by excellence, Copahu balsam was forgotten after the discovery of penicillin. It is, however, still part of the traditional materia medica that has remained in use in Amazonia and French Guiana.

The Brazilian herbal medicine system is one of many traditional practices that uses the resin medicinally as a powerful antiseptic and expectorant for respiratory tract problems — and as an internal anti-inflammatory for urinary tract issues and external anti-inflammatory agent for all kinds of skin problems.

Ethnopharmacological indications across Copaifera spp. include treatment of gonorrhea, bronchitis, asthma, skin ulcers, sore throat, uterine infections, general inflammations, cancer, and leishmaniasis.

3. Key Constituents and Active Compounds

Overall Composition

Copaiba oil, an oleoresin obtained from the trunks of Copaifera trees, comprises a volatile fraction dominated by sesquiterpene hydrocarbons (for example β-caryophyllene and α-humulene) and a non-volatile portion rich in diterpene acids (such as copalic, kaurenoic, and polyalthic acids). The resin contains up to 15% volatile oil; the remaining materials are resins and acids. The active biological properties of copaiba resin are attributed to a group of phytochemicals called sesquiterpenes (over 50% of the resin may be sesquiterpenes), diterpenes, and terpenic acids.

Sesquiterpene Hydrocarbons

The copaiba resins are generally composed of a volatile oil made up largely of sesquiterpene hydrocarbons, such as β-caryophyllene, α-copaene, β-elemene, α-humulene, and germacrene D. The oil consists primarily of sesquiterpene hydrocarbons; its main component is β-caryophyllene. The oil also contains significant amounts of α-bergamotene, α-copaene, and β-bisabolene.

Copaiba resin is the highest known natural source of caryophyllene, comprising up to 480,000 parts per million. Caryophyllene is a well-known plant chemical which has been documented with strong anti-inflammatory effects. The oleoresin essential oils from the three primary commercial species can have as much as 33% (C. langsdorffii), 87% (C. officinalis), and 68% (C. reticulata) β-caryophyllene.

Diterpene Acids

In addition, the oleoresin is also made up of several biologically active diterpene acids, including copalic acid, kaurenoic acid, alepterolic acid, and polyalthic acid. The diterpenes most commonly found in copaiba oleoresins are copalic, polyalthic, hardwickiic, kaurenoic, and ent-kaurenoic acids, together with their derivatives 3-hydroxy-copalic, 3-acetoxy-copalic, and ent-agathic.

Copalic acid is considered a biomarker for the genus Copaifera, and some studies have been performed to evaluate the antibacterial activities of this substance. It has been demonstrated to have significant antimicrobial activity against B. subtilis, S. aureus, and S. epidermidis. Kaurenoic acid has been reported to exert anti-inflammatory, hypotensive, and diuretic effects in vivo and antimicrobial, smooth muscle relaxant, and cytotoxic actions in vitro. Diterpenes comprise bioactive molecules such as copalic acid, kaurenoic acid, and hardwickiic acid, which exhibit documented cytotoxic, anti-inflammatory, and antimicrobial effects.

Copaiba is also the primary source of copalic acid. Kaurenoic acid [ent-kaur-16-en-19-oic acid] is a diterpene that occurs naturally in some Brazilian plants, including Copaifera oleoresins.

4. Mechanisms of Action

β-Caryophyllene (BCP) and the Endocannabinoid System

BCP is a dietary sesquiterpene and highly selective CB2 agonist with negligible CB1 activity, abundant in essential oils of black pepper, clove, oregano, copaiba, and Cannabis sativa. CB2 receptors are enriched on peripheral immune cells, keratinocytes, fibroblasts, sebocytes, and small-diameter sensory fibers, while their expression in the central nervous system (CNS) remains minimal. This peripheral bias enables selective CB2 agonists to exert anti-inflammatory and antipruritic effects without the psychotropic risks associated with CB1 activation.

β-Caryophyllene is a ligand of cannabinoid receptor 2 (CB2); its activation has been associated with decreasing pain, a major signal of inflammatory response, and enhancing re-epithelization. The mechanisms of action of BCP remain uncertain, possibly including full agonism at the cannabinoid CB2 receptor (CB2R). Another potential target is the peroxisome proliferator-activated receptor (PPAR).

CB2-Mediated Signaling Pathways

Copaiba essential oil upregulated the pI3K/Akt/mTOR, MAPK, and JAK/STAT signaling pathways in neuronal cells. The effects of copaiba essential oil peaked at 30 min post-treatment, with a half-maximal effective concentration (EC50) of approximately 80 ng/mL. Treatment with cannabinoid receptor 2 (CB2) agonist AM1241 or the inverse agonist BML190 abrogated the regulatory effects of copaiba essential oil on the pI3K/Akt/mTOR signaling pathway. The biological activities of copaiba essential oil were determined to be fast acting, CB2 mediated, and dependent on multiple chemical constituents of the oil.

Anti-Inflammatory Mechanisms

Anti-inflammatory effects arise from modulation of cytokine cascades and inhibition of pro-inflammatory enzymes, while antioxidant mechanisms support tissue repair and re-epithelization in wound-healing models. In animal arthritis models, BCP significantly hampered the severity of the disease, reduced relevant pro-inflammatory cytokines, and increased the anti-inflammatory cytokine IL-13. BCP also decreased joint expression of matrix metalloproteinases 3 and 9.

The wound-healing activity of copaiba oleoresin can be mainly attributed to the anti-inflammatory activity of β-caryophyllene — since it is commonly the predominant compound found in oleoresins from the Copaifera species — but also to the synergistic activity of the β-caryophyllene with the α-humulene. The α-humulene has been related with the promotion of angiogenesis, helpful in wound healing.

Antimicrobial Mechanisms

Antimicrobial properties span both planktonic and biofilm-associated Gram-positive bacteria, with diterpene acids demonstrating low micromolar minimum inhibitory concentrations against key pathogens. Given that Copaifera oleoresins contain many easily deprotonable acid terpenes, the presence of this class of compounds in the oleoresins might contribute to the antibacterial activity observed.

5. Scientific Evidence by Area of Use

5.1 Anti-Inflammatory and Analgesic Activity

The anti-inflammatory activity of copaiba is one of the most extensively studied pharmacological properties across the literature. In vivo studies (mainly animal models) represent the most common type of medical study (n = 36).

Animal and Pre-clinical Evidence: The first medical study investigated the anti-inflammatory effect of C. reticulata Ducke on carrageenin-induced pedal edema in rats (Basile et al., 1988). The oral administration of copaiba oleoresin has also shown peripheral and central antinociceptive effects in pain models, such as in the acetic acid-induced abdominal constriction, formalin, and tail flick tests. The antinociceptive activity of copaiba oleoresin in these studies was attributed to its anti-inflammatory effect and interactions with opioid receptors.

Human Clinical Evidence: Three out of six clinical trials found in a comprehensive review originated from the medical field. These trials have a considerably higher certainty of evidence than in vitro and in vivo studies; however, a low number of clinical trials were published. In 2018, a clinical trial showed the analgesic and anti-inflammatory effects of copaiba essential oil used for hand massage in individuals with arthritis and osteoarthritis (Bahr et al., 2018).

Evidence strength: Predominantly animal/in vitro for mechanisms; limited human clinical trials with positive but preliminary results for arthritis-related pain. High-quality human RCT evidence remains sparse.

5.2 Skin Health: Acne, Wound Healing, and Scarring

Acne: A placebo-controlled clinical trial conducted in 2012 showed that copaiba essential oil reduced the face area affected by acne (da Silva et al., 2012). This represents one of the few published placebo-controlled trials in the human literature.

Wound Healing and Oral Cavity: Two studies reported beneficial wound healing effects, such as early reduction in the wound area and greater immature bone formation in rats' mandibles; and two related beneficial anti-inflammatory effects, including reduced acute inflammatory reaction and more advanced tissue repair stage, early formation of collagen fibrils, with greater quantity, thickness, and better organization. Based on the articles, benefits related to wound healing and anti-inflammatory effects in the oral cavity of rats treated with copaiba oleoresin were suggested. However, due to the limited data, future studies are necessary, especially clinical ones.

Scarring: A prospective, randomized, double-blind, and placebo-controlled clinical trial showed that the use of a copaiba oil-containing silicone-based gel for 84 days improved the color, contour, distortion, and texture of different types of scars (Waibel et al., 2021).

UVB/Burn-Associated Pain: In a UVB sunburn mouse model, a 3% copaiba cream — GC-MS verified to contain BCP among major sesquiterpenes — attenuated mechanical allodynia (approximately 65% inhibition on day 2) and abolished thermal hyperalgesia, with reduced leukocyte infiltration.

Evidence strength: A small number of human trials support skin-related applications (acne, scarring), with animal data supporting wound healing. The total body of controlled human evidence remains limited.

5.3 Antimicrobial Activity

Antibacterial: Copaiba oleoresin was tested against Gram-positive (Staphylococcus aureus, Streptococcus pyogenes, Enterococcus faecalis) and Gram-negative (Pseudomonas aeruginosa and Escherichia coli) bacteria related to infections in cutaneous wounds. Copaiba oleoresin showed antimicrobial activity only against the Gram-positive bacteria, with MIC of 200 μg/mL, 400 μg/mL, and 1100 μg/mL for S. aureus, S. pyogenes, and E. faecalis, respectively. This confirmed the antimicrobial effects of the C. reticulata oleoresin and its diterpenoid constituents.

Copaiba oleoresin from C. multijuga showed antimicrobial activity against E. coli, S. aureus, and P. aeruginosa. However, other studies did not observe any activity of the copaiba oleoresin from C. multijuga against S. aureus, and another copaiba oleoresin (species not identified) showed no activity against B. subtilis and S. aureus. These conflicting findings across studies likely reflect interspecies and batch-to-batch variation in chemical composition.

Antifungal: Copaiba oleoresin from C. langsdorffii showed moderate fungicidal activity against T. mentagrophytes ATCC 11481 (MIC and MFC = 170 μg mL⁻¹) and weak fungicidal activity against T. rubrum CCT 5507 (MIC = 1,360 μg mL⁻¹ and MFC = 2,720 μg mL⁻¹). There was no activity against M. canis ATCC 32903 and M. gypseum ATCC 14683. SEM analysis revealed physical damage and morphological alterations such as compression and hyphae clustering in the structure of the fungi exposed to the action of the oleoresin.

Evidence strength: Predominantly in vitro, with conflicting results across species. No large-scale controlled human antimicrobial clinical trials have been published as of the available literature.

5.4 Oral Health

The number of studies in the oral science field has been constantly growing due to the potential antimicrobial effect of copaiba, especially against oral pathogens. Recent studies demonstrated that copaiba oleoresin has antioxidative, healing, bone formation stimulant, cytotoxic, gastroprotective, nociceptive, antimicrobial, antileishmanial, antiedema, antifungal, antiblennorrhagic, anthelmintic, and antiseptic properties.

Evidence strength: Mostly preclinical (animal) studies; limited clinical trials in oral medicine are emerging but insufficient for definitive conclusions.

5.5 Neurological and Stress-Related Effects

A randomized clinical trial of copaiba oil inhalation in adults under high mental workload reduced heart rate, salivary cortisol, and beta waves in the left medial frontal region, consistent with body relaxation (Zhang et al., 2022). This represents a single human RCT in aromatherapy, and results should be interpreted cautiously.

BCP has been investigated in behavioral paradigms including drug self-administration, conditioned place preference, and intracranial self-stimulation; the drugs tested were cocaine, nicotine, alcohol, and methamphetamine. BCP prevented or reversed behavioral changes resulting from drug exposure. Preclinical studies have reported promising results with BCP in animal models of substance use disorders. Further research, including studies in humans, are warranted to establish its therapeutic potential and its mechanisms of action.

Evidence strength: Animal models show preliminary neuroprotective and stress-modulating signals. A single human aromatherapy RCT exists. No robust human clinical trials in neurology or addiction have been published.

5.6 Neuroprotection

In an animal study, copaiba oil-resin (COR) is obtained by tapping the trunk of the trees from several Copaifera L. species (Leguminoseae). These oleoresins have been traditionally used as healing and anti-inflammatory agents in Brazilian folk medicine. Research demonstrated that copaiba oil-resin reduced neutrophil recruitment and microglial activation after motor cortex excitotoxic injury, suggesting neuroprotective mechanisms. These findings are preclinical only.

5.7 Liver-Related Conditions

Copaiba oleoresin supplementation in a cirrhosis animal model improved cirrhosis-associated cachexia by increasing weight gain and body fat, and also attenuated systemic inflammation. The liver showed higher levels of IL-10, a protein that helps reduce inflammation. This evidence is animal-model only.

Evidence strength: Preclinical only; no human clinical data available for hepatic indications.

6. Body Systems and Health Areas

• Musculoskeletal / Inflammatory: Copaíba continues to be an object of medical research for its potential antibiotic, anti-inflammatory, antirheumatic, and antitumor properties.
• Integumentary (Skin): Antioxidative, healing, bone formation stimulant, antimicrobial, antiedema, antifungal, and antiseptic properties.
• Respiratory: For centuries, South Americans have used copaiba resin to promote the health of the respiratory, digestive, urinary, cardiovascular, and immune systems.
• Urinary: People take copaiba balsam for treating bronchitis, hemorrhoids, constipation, diarrhea, and bladder infections and other urinary tract infections (UTIs).
• Neurological: CB2-mediated neuronal signaling modulation observed in in vitro and animal research.
• Oral / Dental: Growing evidence base in oral antimicrobial and wound-healing applications.
• Endocannabinoid system: CB2 is one of the two main receptors of the endocannabinoid system. Beta-caryophyllene illustrates the benefits of CB2 receptor activation.

7. Dosage Forms and Reported Doses in Studies

Copaiba supplements are available in capsules or softgels that contain standardized amounts of copaiba oleoresin. Topical formulations including creams and gels have been used in research, and the raw oleoresin itself — applied directly or diluted — represents another route.

The following doses have been reported in specific published studies:

• In an acute and subacute toxicity study in rodents, acute toxicity was assessed at 2000 mg/kg. In subacute toxicity tests, copaiba oleoresin was administered at daily doses of 25, 50, or 100 mg/kg for 28 days.
• In a collagen antibody-induced arthritis (CAIA) mouse model, animals received BCP at 10 mg/kg/100 μL orally (in corn oil vehicle).
• A dose of 200 mg/kg/day of copaiba oleoresin was administered via gavage in a liver cirrhosis animal model.
• In a developmental toxicity study conducted per OECD Guideline 414, pregnant Wistar rats were treated with COPA-R at 0, 500, 1000, and 1250 mg/kg bw/day by gavage on gestation days 6–19.
• COPA-R was maternally toxic and embryotoxic at the two highest doses, but the study derived an oral NOAEL for maternal and developmental toxicity of 500 mg/kg bw/day. The results suggest that copaiba oleoresin does not pose a health risk to pregnant women when used according to the recommended doses (up to five drops, three times a day).
• In a UVB sunburn mouse model, a 3% copaiba cream was applied topically.

No standardized human clinical oral dosing regimens have been formally established across well-powered human trials. The dosage of commercial supplements varies depending on the manufacturer.

8. Safety Considerations and Interactions

General Toxicity Profile

No toxicological effects were observed in body weight gain, feed and water intake, gross necropsy, relative organ weight, histopathology, hematology, or biochemistry parameters in a 28-day rodent study at doses of 25, 50, or 100 mg/kg. At all three doses, an alkaline phosphatase reduction was observed, which might indicate hepatic protection. The commercial copaiba oleoresin has a low risk of toxicity and did not induce treatment-related adverse effects after short-term daily exposures to a dose two thousand times higher than folk use.

Adverse Effects at High Oral Doses

High doses of oral copaiba oleoresin may cause several adverse effects including gastric irritation, diarrhea, sialorrhea, central nervous system depression, metabolic and liver changes, and body weight gain reduction when administered systemically. Copaiba balsam can cause side effects such as stomach pains, vomiting, and diarrhea.

Reproductive and Developmental Toxicology

The estimated safe exposure level for humans, based on the non-observed adverse effect level (NOAEL) found in guinea pigs for maternal and developmental toxicity, was 500 mg/kg/day. For females of reproductive age, the estimated safe dose for oral administration is 5 mg/kg/day.

The effects on reproductive performance following oral administration of C. multijuga oleoresin in male Wistar rats at 200, 500, and 2500 mg/kg/day doses were evaluated during eight weeks with no signs of toxicity. Treated rats were mated with untreated females and no stillborns or fetal malformations were found, which indicates absence of externally visible teratogenic effects. Results confirmed that oral treatment at the concentrations evaluated did not induce toxic effects on the male reproductive system, on the animals' fertility, nor on the development of their offspring.

Toxicological Evidence Gaps

Despite being used for medicinal purposes via topical and oral application, the toxic effects of copaiba oils and their constituents are little known. For diterpenes, which are less common in other plant species, many of which are produced in a very specialized way in the Copaifera genus, in vitro studies predominate in the literature.

Topical Safety

Pruritic outcomes appear receptor- and dose-dependent: high-dose topical BCP induced dermatitis-like changes with pruritus in mice. This indicates that topical dosing concentration matters for skin tolerability.

Regulatory and Food Use Status

β-Caryophyllene, the primary bioactive sesquiterpene of copaiba, is approved to be used as a natural flavoring agent by the FDA. Beta-caryophyllene (β-caryophyllene, BCP) is a bicyclic sesquiterpene extracted from copaiba (Copaifera spp.) and marijuana/hemp (Cannabis spp.) that has received approval by the Food and Drug Administration (FDA) because of its intriguing therapeutic potential. BCP is currently used as a food additive, although pharmacological studies suggest its potential therapeutic application for the treatment of certain brain disorders.

Potential Drug Interactions

No large-scale human pharmacokinetic drug interaction studies with copaiba have been published in the available peer-reviewed literature. People use copaiba balsam for dental cavities, osteoarthritis, rheumatoid arthritis, UTIs, wound healing, and many other conditions, but there is no good scientific evidence to support these uses. Given its CB2 agonist activity, theoretical pharmacodynamic interactions with immunosuppressants and cannabinoid-active drugs are plausible, but have not been formally characterized in human studies.

Adulteration and Standardization Concerns

Inconsistencies in reported chemical composition and physicochemical properties across studies highlight the lack of standardized characterization and extraction methods. The presence of copalic acid (1.0%) is described as an originality marker, ensuring that the oil comes from trees of genus Copaifera spp. This marker is used to authenticate genuine copaiba preparations from potential adulterants.

References

• Da Trindade R, da Silva JK, Setzer WN. Copaifera of the Neotropics: A Review of the Phytochemistry and Pharmacology. Int J Mol Sci. 2018;19(5):1511. PMC5983702
• Pieri FA, et al. Chemistry and Biological Activities of Terpenoids from Copaiba (Copaifera spp.) Oleoresins. Molecules. 2018. PMC6269112
• Leite RS, et al. Anti-inflammatory and wound healing effect of Copaiba oleoresin on the oral cavity: A systematic review. J Ethnopharmacol. 2022. PMC8873535
• Comprehensive review: Evaluation of the biological activities of Copaiba (Copaifera spp): a comprehensive review based on scientometric analysis. Front Pharmacol. 2023. PMC10502340
• Fast-Acting and Receptor-Mediated Regulation of Neuronal Signaling Pathways by Copaiba Essential Oil. PMC7177672
• β-Caryophyllene Mitigates Collagen Antibody Induced Arthritis (CAIA) in Mice Through a Cross-Talk between CB2 and PPAR-γ Receptors. PMC6723248
• β-Caryophyllene, a CB2-Receptor-Selective Phytocannabinoid, Suppresses Mechanical Allodynia in a Mouse Model of Antiretroviral-Induced Neuropathic Pain. PMC6983198
• Effects of β-caryophyllene, A Dietary Cannabinoid, in Animal Models of Drug Addiction. PMC10190141
• Safety and Effectiveness of Copaiba Oleoresin (C. reticulata Ducke) on Inflammation and Tissue Repair of Oral Wounds in Rats. PMC7278981
• Toxicological Effects of Copaiba Oil (Copaifera spp.) and Its Active Components. PMC10005474
• Antifungal Activity of Copaifera langsdorffii Desf Oleoresin against Dermatophytes. PMC6270220
• In vitro studies of the antibacterial activity of Copaifera spp. oleoresins against clinical and environmental isolates recovered from a hemodialysis unit. PMC5782372
• Topical β-Caryophyllene for Dermatologic Disorders: Mechanisms, Human Evidence, and Clinical Translation. PMC12655451
• Copaiba Oil-Resin Treatment Is Neuroprotective and Reduces Neutrophil Recruitment and Microglia Activation after Motor Cortex Excitotoxic Injury. PMC3291111
• Copaiba Oleoresin Improves Weight Gain and IL-10 Concentration, with No Impact on Hepatic Histology, in Liver Cirrhosis. PMC11591688
• Developmental toxicity of copaiba tree (Copaifera reticulata Ducke, Fabaceae) oleoresin in rat. PubMed PMID 21266184
• Acute and a 28-repeated dose toxicity study of commercial oleoresin from Copaifera sp. in rodents. Adv Tradit Med. 2021.
• Copaiba oleoresin has topical antinociceptive activity in a UVB radiation-induced skin-burn model in mice. J Ethnopharmacol. 2020.
• Copaiba — Wikipedia
• Copaiba Balsam — RxList
• Investigation of Safety Profile of Four Copaifera Species and of Kaurenoic Acid by Salmonella/Microsome Test. PMC6348810
• Meta-analysis on Copaiba Oil: Its Functions in Metabolism and Its Properties as an Anti-inflammatory Agent. ResearchGate
• Exploring Copaiba and Andiroba Oils: A Comprehensive Review of Composition, Physicochemical Properties and Pharmacological Activities in Advanced Delivery Systems. Pharmaceutics. 2025.